Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Lenvatinib plus PD-1 inhibitor combination therapy has emerged as a frontline treatment for advanced hepatocellular carcinoma (HCC), but substantial interpatient variability in therapeutic responses underscores the urgent need for reliable predictive biomarkers.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
